Safety of an extended-release injectable moxidectin suspension formulation (ProHeart® 12) in dogs

Safety of an extended-release injectable moxidectin suspension formulation (ProHeart® 12) in dogs

Abstract Background The safety of ProHeart® 12 (PH 12; extended-release injectable suspension; 10% moxidectin in glyceryl tristearate microspheres) was evaluated in four studies using Beagle dogs and one study using ivermectin-sensitive Collies. The recommended dose is 0.5 mg/kg subcutaneously once...

Full description

Bibliographic Details
Main Authors: Matthew J. Krautmann, Sean Mahabir, Ann Fielder, Wendy Collard, Tracie L. Wolthuis, Kevin Esch, Tracy Morton, Kent Alleman, Laibin Luo, Erin McCandless, Steven Nederveld, Kristina Kryda, Ryan Carroll, Joseph F. Boucher
Format: Article
Language:English
Published: BMC 2019-09-01
Series:Parasites & Vectors
Subjects:
ProHeart® 12
ProHeart® SR-12
Moxidectin
Safety
Toxicology
Dog
Online Access:http://link.springer.com/article/10.1186/s13071-019-3690-6

Internet

http://link.springer.com/article/10.1186/s13071-019-3690-6

Similar Items